Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
J Gastroenterol Hepatol. 2012 Oct;27(10):1581-8. doi: 10.1111/j.1440-1746.2012.07151.x.
Renal insufficiency (RI) often coexists with hepatocellular carcinoma (HCC) and predicts a poor outcome in patients receiving transarterial chemoembolization (TACE). The modification of diet in renal disease (MDRD) and chronic kidney disease epidemiology collaboration (CKD-EPI) equations are used to provide estimated glomerular filtration rate (eGFR). This study aimed to determine a prognsotic renal surrogate for outcome prediction in HCC patients receiving TACE.
A total of 684 patients with HCC undergoing TACE were retrospectively analyzed. The prognostic ability between the MDRD and CKD-EPI equation was compared by the Akaike information criterion (AIC).
Patients were categorized by eGFR into > 60, 30-60 and < 30 mL/min per 1.73 m(2) (equivalent to CKD stages 1-2, 3, and 4-5, respectively) groups. The eGFR generated by the MDRD equation had a better predictive accuracy by having a lower AIC score (3234.5) compared to the CKD-EPI equation (3236.7). The adjusted risk ratio for patients with eGFR 30-60 mL/min per 1.73 m(2) by the MDRD was 1.313 (P = 0.041) compared with patients with eGFR > 60 mL/min per 1.73 m(2) in the multivariate Cox model. The eGFR defined by the MDRD equation consistently had better prognostic ability when patients were stratified by the Child-Turcotte-Pugh score of 5 and > 5 and Cancer of the Liver Italian Program score 0 to 1 and > 1.
The eGFR according the MDRD equation may provide better prognostic accuracy than the CKD-EPI equation independent of liver functional reserve and tumor staging, and is a more feasible renal surrogate for outcome prediction in CKD stage 1-3 HCC patients receiving TACE.
肾功能不全(RI)常与肝细胞癌(HCC)共存,并预测接受经动脉化疗栓塞(TACE)治疗的患者预后不良。改良肾脏病饮食(MDRD)和慢性肾脏病流行病学合作(CKD-EPI)方程用于提供估算肾小球滤过率(eGFR)。本研究旨在确定 TACE 治疗 HCC 患者预后预测的替代肾指标。
回顾性分析 684 例接受 TACE 的 HCC 患者。通过赤池信息量准则(AIC)比较 MDRD 和 CKD-EPI 方程的预后能力。
根据 eGFR 将患者分为>60、30-60 和<30mL/min/1.73m2(分别相当于 CKD 1-2、3 和 4-5 期)组。MDRD 方程生成的 eGFR 通过具有较低的 AIC 评分(3234.5),预测准确性优于 CKD-EPI 方程(3236.7)。MDRD 方程的 eGFR 为 30-60mL/min/1.73m2 的患者的调整风险比为 1.313(P=0.041),与 eGFR>60mL/min/1.73m2 的患者相比。在多变量 Cox 模型中,当患者按 Child-Turcotte-Pugh 评分 5 和>5 和意大利肝癌计划评分 0 至 1 和>1 分层时,MDRD 方程定义的 eGFR 始终具有更好的预后能力。
MDRD 方程的 eGFR 可能比 CKD-EPI 方程提供更好的预后准确性,独立于肝储备功能和肿瘤分期,是 TACE 治疗 CKD 1-3 期 HCC 患者预后预测的更可行的替代肾指标。